ACRES Commercial Realty Corp. (ACR)

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that clinical data from the Phase 3 study in China evaluating telitacicept in adults with primary Sjögren's disease, a study sponsored by Vor's collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331), will be presented as a late-breaking poster presentation at ACR Convergence 2025, being held October 24-29, 2025, at McCormick Place in Chicago, Illinois.

Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025 Highlights discovery of novel targets in T cell-driven autoimmune disorders; initial findings to be presented at the ACR Convergence 2025

Autolus announces the publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2025, to be held October 24-29, 2025.

UNIONDALE, N.Y. , Sept. 15, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

ACRES Commercial Realty reported second-quarter book value per share that dipped by 57 cents sequentially. The common shares are trading at a 25% discount to book value. The mREIT bought back $5.1 million of shares at a roughly 33% discount during the second quarter. There is just over $5 million of capacity left in the buyback program. I expect ACR to expand the program against management's objective to continue to book value.

Zefiro has made a key breakthrough by successfully originating carbon credits based on confirmed emissions reductions of 92,956 metric tonnes of CO2 equivalent from a remediation project in Custer County, Oklahoma. Zefiro has also made its first delivery of carbon credits to Mercuria Energy America, LLC to fulfill a pre-sale agreement.

Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types

ACRES Commercial Realty Corp. (NYSE:ACR ) Q2 2025 Earnings Conference Call July 31, 2025 10:00 AM ET Company Participants Andrew Dodd Fentress - Chairman of the Board Eldron C. Blackwell - CFO & Senior VP Kyle K.

UNIONDALE, N.Y. , July 30, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company"), a real estate investment trust that is primarily focused on originating, holding and managing commercial real estate mortgage loans and equity investments in commercial real estate property through direct ownership and joint ventures, today reported results for the quarter ended June 30, 2025.

UNIONDALE, N.Y. , July 16, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the second quarter 2025, on Wednesday, July 30, 2025, after the market closes.

ACRES Commercial Realty has been aggressively buying back its common shares and recently extended its buyback authorization by $10 million. The mREIT does not pay a dividend, but returns have been positive on the back of its backpack program. A continued reduction of its CRE loan portfolio presents a risk for bulls as originations continue to lag payoffs.

UNIONDALE, N.Y. , June 5, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.

Agreement would extend Nexxen's global ACR data exclusivity with VIDAA, while adding display ad monetization exclusivity across VIDAA's media in North America Agreement would extend Nexxen's global ACR data exclusivity with VIDAA, while adding display ad monetization exclusivity across VIDAA's media in North America

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose escalation cohorts completed in ACR-2316 Phase 1 trial with tumor shrinkage observed already at dose level (DL)3, below projected recommended Phase 2 dose AACR presentation of ACR-2316 revealing mechanisms underlying its superior preclinical activity with potent mitotic tumor cell death using AP3 Generative Phosphoproteomics Mansoor Raza Mirza, M.D. appointed chief medical officer; accomplished clinician with stellar track record of successfully leading registrational trials through regulatory approvals, and establishing new standards of care in gynecological oncology Cash, cash equivalents and marketable securities of $164.8 million as of March 31, 2025, expected to fund operations into the second quarter of 2027 WATERTOWN, Mass.

ACRES Commercial Realty Corp. (NYSE:ACR ) Q1 2025 Earnings Call May 1, 2025 10:00 AM ET Company Participants Kyle Brengel - Vice President, Operations Mark Fogel - President and Chief Executive Officer Eldron Blackwell - Chief Financial Officer Andrew Fentress - Chairman Conference Call Participants Matthew Erdner - Jones Trading Chris Muller - Citizens Capital Markets Operator Good day, ladies and gentlemen and welcome to the First Quarter 2025 ACRES Commercial Realty Corp. Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded.

UNIONDALE, N.Y. , April 30, 2025 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $10 million of the outstanding shares of both its common and preferred stock.